News
Publications
Multimedia
Conferences
Webcasts
Resources
Subscribe

Spotlight -

Drug Development|

Quality Systems

Rick L. Friedman

Rick L. Friedman, MS, is Deputy Director for Manufacturing Quality, FDA Center for Drug Evaluation & Research.

Articles by Rick L. Friedman

Risk Management and Assessment for Business Investment Concept. Modern graphic interface showing symbols of strategy in risky plan analysis to control unpredictable loss and build financial safety.| Image credit: Summit Art Creations - stock.adobe.com

ICH Q9: Attaining a Quality-Business Synergy through Quality Risk Management, ROI Analysis, and Highly Capable Facilities

ByRick L. Friedman,David Lebo,Lawrence Liberti,GK Raju

January 15th 2024

This paper explores the relationship between investing in pharmaceutical manufacturing risk reduction and meeting business objectives.

Latest Updated Articles

ICH Q9: Attaining a Quality-Business Synergy through Quality Risk Management, ROI Analysis, and Highly Capable Facilities
Published: January 15th 2024 | Updated:

Trending on Pharmaceutical Technology

Outsourcing Partners Providing End-to-End Service

Kimberly-Clark to Buy Tylenol Maker Kenvue: Analyzing Risks and Rewards

Integrating Sustainability into the Core of Pharmaceutical Science

© 2025 MJH Life Sciences^®

All rights reserved.